 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN SODIUM increase or decrease the risk of [0m
[34mhospitalization?[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrecipient_message[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"recipient_message"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"intended_recipient"[0m[32m: [0m[32m"FDAHandler"[0m[32m,[0m
[32m    [0m[32m"content"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of hospitalization?"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDoes PHENYTOIN SODIUM increase or decrease the risk of [0m
[32mhospitalization?[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDoes PHENYTOIN SODIUM increase or decrease the risk of hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"PHENYTOIN SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Below are some relevant extracts for your query:[0m
[31m        -----[0m
[31m        [0m
[31mCONTENT: PHENYTOIN SODIUM: pregnancy: [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure Registry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m,[0m
[31msuch as Phenytoin Sodium Injection, during pregnancy. Physicians are advised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy [0m
[31mRegistry. This can be done by calling the toll free number [0m[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. Information on the registry can also be found at the website [0m
[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal [0m
[31mphenytoin exposure is associated with an increased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. PHENYTOIN SODIUM: pregnancy: In addition, the fetal hydantoin [0m
[31msyndrome a pattern of abnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported [0m
[31mamong children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including [0m
[31mneuroblastoma, in children whose mothers received phenytoin during pregnancy. Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal malformations and other [0m
[31mmanifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In the U.S. general [0m
[31mpopulation, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. PHENYTOIN SODIUM: pregnancy: The [0m
[31mbackground risk of major birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur [0m
[31mduring pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate [0m
[31madjustment of dosage [0m[31m . However, postpartum restoration of the original dosage will probably be indicated. Fetal/Neonatal adverse reactions A potentially life-threatening bleeding disorder related to [0m
[31mdecreased levels of vitamin K-dependent clotting factors may occur in newborns exposed to phenytoin in utero . This drug-induced condition can be prevented with vitamin K administration to the mother [0m
[31mbefore delivery and to the neonate after birth. Data Human Data Meta-analyses using data from published observational studies and registries have estimated an approximately [0m[1;31m2[0m[31m. PHENYTOIN SODIUM: [0m
[31mpregnancy: [0m[1;31m4[0m[31m-fold increased risk for any major malformation in children with prenatal phenytoin exposure compared to controls. An increased risk of heart defects, facial clefts, and digital hypoplasia[0m
[31mhas been reported. The fetal hydantion syndrome is a pattern of congenital anomalies including craniofacial anomalies, nail and digital hypoplasia, prenatal-onset growth deficiency, and [0m
[31mneurodevelopmental deficiencies. Animal Data Administration of phenytoin to pregnant rats, rabbits, and mice during organogenesis resulted in embryofetal death, fetal malformations, and decreased [0m
[31mfetal growth retardation. Malformations [0m[1;31m([0m[31mincluding craniofacial, cardiovascular, neural, limb, and digit abnormalities[0m[1;31m)[0m[31m were observed in rats, rabbits, and mice at doses as low as [0m[1;31m100[0m[31m, [0m[1;31m75[0m[31m, and [0m[1;31m12.5[0m[31m [0m
[31mmg/kg, respectively.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: warnings_and_cautions: In all cases of lymphadenopathy, follow-up observation for an extended period is indicated and every effort should be made to achieve seizure control [0m
[31musing alternative antiepileptic drugs. [0m[1;31m5.8[0m[31m Local Toxicity [0m[1;31m([0m[31mIncluding Purple Glove Syndrome[0m[1;31m)[0m[31m Soft tissue irritation and inflammation has occurred at the site of injection with and without extravasation[0m
[31mof intravenous phenytoin. Edema, discoloration and pain distal to the site of injection [0m[1;31m([0m[31mdescribed as â€œpurple glove syndromeâ€[0m[1;31m)[0m[31m have also been reported following peripheral intravenous phenytoin [0m
[31minjection. Soft tissue irritation may vary from slight tenderness to extensive necrosis, and sloughing. The syndrome may not develop for several days after injection. Although resolution of symptoms [0m
[31mmay be spontaneous, skin necrosis and limb ischemia have occurred and required such interventions as fasciotomies, skin grafting, and, in rare cases, amputation. PHENYTOIN SODIUM: [0m
[31mwarnings_and_cautions: Because of the risk of local toxicity, intravenous Phenytoin Sodium Injection should be administered directly into a large peripheral or central vein through a large-gauge [0m
[31mcatheter. Prior to the administration, the patency of the IV catheter should be tested with a flush of sterile saline. Each injection of parenteral Phenytoin Sodium Injection should then be followed [0m
[31mby a flush of sterile saline through the same catheter to avoid local venous irritation caused by the alkalinity of the solution. Intramuscular Phenytoin Sodium Injection administration may cause [0m
[31mpain, necrosis, and abscess formation at the injection site [0m[31m . [0m[1;31m5[0m[31m. PHENYTOIN SODIUM: warnings_and_cautions: [0m[1;31m9[0m[31m Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is[0m
[31mincreased in patients with renal or hepatic disease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m5.10[0m[31m [0m
[31mExacerbation of Porphyria In view of isolated reports associating phenytoin with exacerbation of porphyria, caution should be exercised in using this medication in patients suffering from this [0m
[31mdisease. [0m[1;31m5.11[0m[31m Teratogenicity and Other Harm to the Newborn Phenytoin Sodium Injection may cause fetal harm when administered to a pregnant woman. Prenatal exposure to phenytoin may increase the risks [0m
[31mfor congenital malformations and other adverse developmental outcomes [0m[31m . PHENYTOIN SODIUM: warnings_and_cautions: Increased frequencies of major malformations [0m[1;31m([0m[31msuch as orofacial clefts and cardiac [0m
[31mdefects[0m[1;31m)[0m[31m, and abnormalities characteristic of fetal hydantoin syndrome, including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and [0m
[31mcognitive deficits, have been reported among children born to epileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy. There have been several [0m
[31mreported cases of malignancies, including neuroblastoma. A potentially life-threatening bleeding disorder related to decreased levels of vitamin K-dependent clotting factors may occur in newborns [0m
[31mexposed to phenytoin in utero. This drug-induced condition can be prevented with vitamin K administration to the mother before delivery and to the neonate after birth. [0m[1;31m5.12[0m[31m Hyperglycemia [0m
[31mHyperglycemia, resulting from the drug's inhibitory effect on insulin release, has been reported. PHENYTOIN SODIUM: warnings_and_cautions: Phenytoin may also raise the serum glucose level in diabetic [0m
[31mpatients. [0m[1;31m5.13[0m[31m Serum Phenytoin Levels Above Therapeutic Range Serum levels of phenytoin sustained above the therapeutic range may produce confusional states referred to as [0m[31m"delirium"[0m[31m, [0m[31m"psychosis"[0m[31m, or [0m
[31m"encephalopathy"[0m[31m, or rarely irreversible cerebellar dysfunction and/or cerebellar atrophy. Accordingly, at the first sign of acute toxicity, serum levels should be immediately checked. Dose reduction [0m
[31mof phenytoin therapy is indicated if serum levels are excessive; if symptoms persist, termination is recommended.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: dosage_and_administration: When returned to oral administration, the dose should be reduced by [0m[1;31m50[0m[31m% of the original oral dose for one week to prevent excessive serum levels [0m
[31mdue to sustained release from intramuscular tissue sites. Monitoring serum levels would help prevent a fall into the subtherapeutic range. Serum blood level determinations are especially helpful when [0m
[31mpossible drug interactions are suspected. [0m[1;31m2.4[0m[31m Parenteral Substitution for Oral Phenytoin Therapy When treatment with oral phenytoin is not possible, IV phenytoin can be substituted for oral phenytoin [0m
[31mat the same total daily dose. Phenytoin capsules are approximately [0m[1;31m90[0m[31m% bioavailable by the oral route. Phenytoin is [0m[1;31m100[0m[31m% bioavailable by the IV route. For this reason, serum phenytoin concentrations [0m
[31mmay increase modestly when IV phenytoin is substituted for oral phenytoin sodium therapy. PHENYTOIN SODIUM: dosage_and_administration: The rate of administration for IV phenytoin should be no greater [0m
[31mthan [0m[1;31m50[0m[31m mg per minute in adults and [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min [0m[1;31m([0m[31mor [0m[1;31m50[0m[31m mg per minute, whichever is slower[0m[1;31m)[0m[31m in pediatric patients. When intramuscular administration may be required, a sufficient dose must be [0m
[31madministered intramuscularly to maintain the serum level within the therapeutic range. Where oral dosage is resumed following intramuscular usage, the oral dose should be properly adjusted to [0m
[31mcompensate for the slow, continuing IM absorption to minimize toxic symptoms [0m[31m. Serum concentrations should be monitored and care should be taken when switching a patient from the sodium salt to the [0m
[31mfree acid form. Phenytoin Sodium Injection is formulated with the sodium salt of phenytoin. PHENYTOIN SODIUM: dosage_and_administration: Because there is approximately an [0m[1;31m8[0m[31m% increase in drug content [0m
[31mwith the free acid form over that of the sodium salt, dosage adjustments and serum level monitoring may be necessary when switching from a product formulated with the free acid to a product formulated[0m
[31mwith the sodium salt and vice versa. [0m[1;31m2.5[0m[31m Dosing in Patients with Renal or Hepatic Impairment or Hypoalbuminemia Because the fraction of unbound phenytoin is increased in patients with renal or hepatic[0m
[31mdisease, or in those with hypoalbuminemia, the monitoring of phenytoin serum levels should be based on the unbound fraction in those patients. [0m[1;31m2.6[0m[31m Dosing in Geriatrics Phenytoin clearance is decreased[0m
[31mslightly in elderly patients and lower or less frequent dosing may be required [0m[31m. [0m[1;31m2[0m[31m. PHENYTOIN SODIUM: dosage_and_administration: [0m[1;31m7[0m[31m Dosing During Pregnancy Decreased serum concentrations of phenytoin [0m
[31mmay occur during pregnancy because of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations should be performed during pregnancy, and the Phenytoin Sodium [0m
[31mInjection dosage should be adjusted as necessary. Postpartum restoration of the original dosage will probably be indicated [0m[31m. Because of potential changes in protein binding during pregnancy, the [0m
[31mmonitoring of phenytoin serum levels should be based on the unbound fraction. [0m[1;31m2.8[0m[31m Dosing in Pediatrics A loading dose of [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m mg/kg of Phenytoin Sodium Injection intravenously will usually produce[0m
[31mserum concentrations of phenytoin within the generally accepted serum total concentrations between [0m[1;31m10[0m[31m and [0m[1;31m20[0m[31m mcg/mL [0m[1;31m([0m[31munbound phenytoin concentrations of [0m[1;31m1[0m[31m to [0m[1;31m2[0m[31m mcg/mL[0m[1;31m)[0m[31m. PHENYTOIN SODIUM: [0m
[31mdosage_and_administration: The drug should be injected slowly intravenously at a rate not exceeding [0m[1;31m1[0m[31m to [0m[1;31m3[0m[31m mg/kg/min or [0m[1;31m50[0m[31m mg per minute, whichever is slower.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: openfda: package_ndc         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: drug_interactions: Neuromuscular blocking agents Cisatracurium, pancuronium, rocuronium and vecuronium: resistance to the neuromuscular blocking action of the [0m
[31mnondepolarizing neuromuscular blocking agents has occurred in patients chronically administered phenytoin. Whether or not phenytoin has the same effect on other non-depolarizing agents is unknown. [0m
[31mPrevention or Management : Patients should be monitored closely for more rapid recovery from neuromuscular blockade than expected, and infusion rate requirements may be higher. PHENYTOIN SODIUM: [0m
[31mdrug_interactions: Warfarin Increased and decreased PT/INR responses have been reported when phenytoin is coadministered with warfarin Other Corticosteroids, doxycycline, estrogens, furosemide, oral [0m
[31mcontraceptives, paroxetine, quinidine, rifampin, sertraline, theophylline, and vitamin D Drugs whose level is decreased by phenytoin Antiepileptic drugs a Carbamazepine, felbamate, lamotrigine, [0m
[31mtopiramate, oxcarbazepine Antilipidemic agents Atorvastatin, fluvastatin, simvastatin Antiviral agents Efavirenz, lopinavir/ritonavir, indinavir, nelfinavir, ritonavir, saquinavir Fosamprenavir: [0m
[31mphenytoin when given with fosamprenavir alone may PHENYTOIN SODIUM: drug_interactions: decrease the concentration of amprenavir, the active metabolite. Phenytoin when given with the combination of [0m
[31mfosamprenavir and ritonavir may increase the concentration of amprenavir Calcium channel blockers Nifedipine, nimodipine, nisoldipine, verapamil Other Albendazole [0m[1;31m([0m[31mdecreases active metabolite[0m[1;31m)[0m[31m, [0m
[31mchlorpropamide, clozapine, cyclosporine, digoxin, disopyramide, folic acid, methadone, mexiletine, praziquantel, quetiapine a The effect of phenytoin on phenobarbital, valproic acid and sodium [0m
[31mvalproate serum levels is unpredictable [0m[1;31m7.3[0m[31m Drug/Laboratory Test Interactions Care should be taken when using immunoanalytical methods to measure serum phenytoin concentrations following fosphenytoin [0m
[31madministration.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: use_in_specific_populations: [0m[1;31m8[0m[31m USE IN SPECIFIC POPULATIONS Pregnancy: Prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse [0m
[31mdevelopmental outcomes. [0m[1;31m([0m[31m [0m[1;31m5.11[0m[31m , [0m[1;31m8.1[0m[31m [0m[1;31m)[0m[31m Renal and/or Hepatic Impairment or Hypoalbuminemia: Monitor unbound phenytoin concentrations in these patients. [0m[1;31m([0m[31m [0m[1;31m8.6[0m[31m [0m[1;31m)[0m[31m [0m[1;31m8.1[0m[31m Pregnancy P regnancy Exposure [0m
[31mRegistry There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs [0m[1;31m([0m[31mAEDs[0m[1;31m)[0m[31m, such as Phenytoin Sodium Injection, during pregnancy. Physicians are [0m
[31madvised to recommend that pregnant patients taking phenytoin enroll in the North American Antiepileptic Drug [0m[1;31m([0m[31mNAAED[0m[1;31m)[0m[31m Pregnancy Registry. This can be done by calling the toll free number [0m
[1;31m1[0m[31m-[0m[1;31m888[0m[31m-[0m[1;31m233[0m[31m-[0m[1;31m2334[0m[31m, and must be done by patients themselves. PHENYTOIN SODIUM: use_in_specific_populations: Information on the registry can also be found at the website [0m
[4;31mhttp://www.aedpregnancyregistry.org/[0m[31m . Risk Summary In humans, prenatal exposure to phenytoin may increase the risks for congenital malformations and other adverse developmental outcomes. Prenatal [0m
[31mphenytoin exposure is associated with an increased incidence of major malformations [0m[1;31m([0m[31mincluding orofacial clefts and cardiac defects[0m[1;31m)[0m[31m. In addition, the fetal hydantoin syndrome a pattern of [0m
[31mabnormalities including dysmorphic skull and facial features, nail and digit hypoplasia, growth abnormalities [0m[1;31m([0m[31mincluding microcephaly[0m[1;31m)[0m[31m, and cognitive deficits has been reported among children born to [0m
[31mepileptic women who took phenytoin alone or in combination with other antiepileptic drugs during pregnancy [0m[31m . There have been several reported cases of malignancies, including neuroblastoma, in [0m
[31mchildren whose mothers received phenytoin during pregnancy. PHENYTOIN SODIUM: use_in_specific_populations: Administration of phenytoin to pregnant animals resulted in an increased incidence of fetal [0m
[31mmalformations and other manifestations of developmental toxicity [0m[1;31m([0m[31mincluding embryofetal death, growth impairment, and behavioral abnormalities[0m[1;31m)[0m[31m in multiple species at clinically relevant doses [0m[31m. In [0m
[31mthe U.S. general population, the estimated background risk of major birth defects and of miscarriage in clinically recognized pregnancies is [0m[1;31m2[0m[31m to [0m[1;31m4[0m[31m% and [0m[1;31m15[0m[31m to [0m[1;31m20[0m[31m%, respectively. The background risk of[0m
[31mmajor birth defects and miscarriage for the indicated population is unknown. Clinical Considerations Disease-associated maternal risk An increase in seizure frequency may occur during pregnancy [0m
[31mbecause of altered phenytoin pharmacokinetics. Periodic measurement of serum phenytoin concentrations may be valuable in the management of pregnant women as a guide to appropriate adjustment of dosage[0m
[31m. However, postpartum restoration of the original dosage will probably be indicated.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m


[31mCONTENT: PHENYTOIN SODIUM: geriatric_use: [0m[1;31m8.5[0m[31m Geriatric Use Phenytoin clearance tends to decrease with increasing age [0m[31m . Lower or less frequent dosing may be required [0m[31m.         [0m
[31mSOURCE:PHENYTOIN SODIUM label[0m

[31m        -----[0m
[31m        If NONE of the extracts are relevant, try doing a web search with the[0m
[31m        `relevant_search_extracts` tool/function-call[0m
[31m        [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32m DO-NOT-KNOW[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [32mDO-NOT-KNOW[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mDocumentHandler[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m                Try a web search using the `relevant_search_extracts` tool,[0m
[31m                to see if it can help answer the question.[0m
[31m                [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mrelevant_search_extracts[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"relevant_search_extracts"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"query"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"drug"[0m[32m: [0m[32m"PHENYTOIN SODIUM"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mrelevant_search_extracts[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mNo relevant extracts found for Does PHENYTOIN SODIUM increase or decrease the risk [0m
[31mof hospitalization?[0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.USER [0m
 [1m([0mFDAHandler[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mFDAHandler[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>       LLM[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>FDAHandler[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [34mDO-NOT-KNOW[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0mEntity.USER[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"final_answer"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"question"[0m[32m: [0m[32m"Does PHENYTOIN SODIUM increase or decrease the risk of hospitalization?"[0m[32m,[0m
[32m    [0m[32m"steps"[0m[32m: [0m[1;32m[[0m
[32m      [0m[32m"I sent a query to FDAHandler to determine the effect of phenytoin sodium on the risk of hospitalization."[0m[32m,[0m
[32m      [0m[32m"I have not yet received a response from FDAHandler, which is necessary to provide an informed answer."[0m
[32m    [0m[1;32m][0m[32m,[0m
[32m    [0m[32m"answer"[0m[32m: [0m[32m"DO-NOT-KNOW"[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31m__PASS__:Critic[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0mEntity.LLM[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m[[0m[32mCANNOT RESPOND[0m[1;32m][0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m FDAHandler [0m [1;34mEntity.USER[0m[1m([0mFDAHandler[1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;34m[[0m[34mCANNOT RESPOND[0m[1;34m][0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m [1;34mEntity.USER[0m[1m([0m          [1m)[0m [1m([0m=>    Critic[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0mfinal_answer[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"final_answer"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"question"[0m[34m: [0m[34m"Does PHENYTOIN SODIUM increase or decrease the risk of hospitalization?"[0m[34m,[0m
[34m    [0m[34m"steps"[0m[34m: [0m[1;34m[[0m
[34m      [0m[34m"I sent a query to FDAHandler to determine the effect of phenytoin sodium on the risk of hospitalization."[0m[34m,[0m
[34m      [0m[34m"I have not yet received a response from FDAHandler, which is necessary to provide an informed answer."[0m
[34m    [0m[1;34m][0m[34m,[0m
[34m    [0m[34m"answer"[0m[34m: [0m[34m"DO-NOT-KNOW"[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"final_answer"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mfinal_answer[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m 
[31m        Question: Does PHENYTOIN SODIUM increase or decrease the risk of hospitalization?[0m
[31m        -----[0m
[31m        Reasoning:[0m
[31m        [0m[1;31m1[0m[31m. I sent a query to FDAHandler to determine the effect of phenytoin sodium on the risk of hospitalization.[0m
[1;31m2[0m[31m. I have not yet received a response from FDAHandler, which is necessary to provide an informed answer.[0m
[31m        -----[0m
[31m        Final answer: DO-NOT-KNOW[0m
[31m        [0m
 [1m([0mCritic[1m)[0m [31m Entity.USER [0m
 [1m([0mCritic[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [32mFUNC: [0m[1;32m{[0m
[32m  [0m[32m"name"[0m[32m: [0m[32m"feedback"[0m[32m,[0m
[32m  [0m[32m"to"[0m[32m: [0m[32m""[0m[32m,[0m
[32m  [0m[32m"arguments"[0m[32m: [0m[1;32m{[0m
[32m    [0m[32m"critique"[0m[32m: [0m[32m""[0m
[32m  [0m[1;32m}[0m
[1;32m}[0m
*[1m([0mCritic[1m)[0m [37m Entity.LLM [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m<[0m[1;31mDONE[0m[1;31m>[0m[31m __PASS__[0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Critic [0m [1;34mEntity.USER[0m[1m([0m    Critic[1m)[0m [1m([0m=>     AGENT[1m)[0m [1m([0mX           [1m)[0m   [1;35mFUNC[0m[1m([0m  feedback[1m)[0m [34mFUNC: [0m[1;34m{[0m
[34m  [0m[34m"name"[0m[34m: [0m[34m"feedback"[0m[34m,[0m
[34m  [0m[34m"to"[0m[34m: [0m[34m""[0m[34m,[0m
[34m  [0m[34m"arguments"[0m[34m: [0m[1;34m{[0m
[34m    [0m[34m"critique"[0m[34m: [0m[34m""[0m[34m,[0m
[34m    [0m[34m"request"[0m[34m: [0m[34m"feedback"[0m
[34m  [0m[1;34m}[0m
[1;34m}[0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0m  feedback[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [31mYour reasoning is valid, no feedback was provided.[0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.USER [0m
 [1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [31m Entity.AGENT [0m [1;31mEntity.AGENT[0m[1m([0mEntity.AGENT[1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;31m[[0m[31mCANNOT RESPOND[0m[1;31m][0m
*[1m([0morchestrator-hospitalization-PHENYTOIN SODIUM[1m)[0m [37m Entity.LLM [0m [1;32mEntity.LLM[0m[1m([0m          [1m)[0m [1m([0m=>          [1m)[0m [1m([0mX           [1m)[0m       [1m([0m          [1m)[0m [1;32m<[0m[1;32mDONE[0m[1;32m>[0m[32m DO-NOT-KNOW[0m

[32mThe question asked was whether phenytoin sodium increases or decreases the risk of hospitalization. I initiated a query to FDAHandler to obtain information on the effects of phenytoin sodium on [0m
[32mhospitalization risk. However, I have not received any data or response from FDAHandler that would enable me to provide a substantiated answer. Therefore, without specific information from the FDA [0m
[32mlabel data, I cannot determine the effect of phenytoin sodium on the risk of hospitalization.[0m
